Fewer than four months after researchers presented retrospective cohort data at the American Heart Association Scientific Sessions in Chicago, investigators are weighing metformin as a low-cost shield against vascular endothelial growth factor inhibitor cardiotoxicity, HCPLive reported.
Vascular endothelial growth factor inhibitors routinely disrupt endothelial nitric oxide production and cellular energy homeostasis, leaving patients vulnerable to left ventricular systolic dysfunction, cardiomyopathy, and heart failure. Researchers found that matched cohorts showed lower all-cause mortality at 19.8% versus 23.0%, alongside new-onset metastatic cancer at 10.6% versus 12.8%.
Haroun pointed out that metformin activates endothelial nitric oxide synthase and increases nitric oxide production. This action provides a near-direct antagonism of the mechanism driven by VEGF inhibitors.
“It’s a low-cost medication. It’s not associated with many side effects. So it’s an opportunity to add it to our toolbox,” Haroun said.
Beyond the endothelium, VEGF inhibitors cause off-target inhibition of AMP-activated protein kinase, a key cellular energy regulator. Metformin steps in as a known AMPK activator to restore energy balance.
Haroun acknowledged the limits of using a composite endpoint for these retrospective findings. Standardized echocardiographic surveillance is more reliable, but the underlying database lacked the granularity required to support it.
The analysis specifically tracked left ventricular systolic dysfunction, cardiomyopathy, and heart failure. Hypertension and other VEGFi-related toxicities fell outside the scope of this evaluation.
“I’m a little cautious about using metformin in patients who do not have diabetes or do not have an indication for metformin,” Haroun said.
Data from the landmark New England Journal of Medicine study published on February 7, 2002, demonstrated that lifestyle intervention and metformin reduce the incidence of type 2 diabetes. Haroun said that the Diabetes Prevention Program proved most helpful in younger patients, individuals with a body mass index above 35, and those presenting with an elevated hemoglobin A1c.
When researchers limited their updated analysis strictly to patients with type 2 diabetes, the mortality and metastatic disease signals disappeared. However, the observed association between metformin and the heart failure composite persisted in that specific population.
No randomized trials have tested metformin specifically for cardioprotection in cardio-oncology settings yet. Haroun favors a randomized trial comparing metformin directly with other diabetes therapies.
The retrospective analysis focused specifically on left ventricular systolic dysfunction, cardiomyopathy, and heart failure.
The mortality and metastatic disease signals disappeared when researchers updated the analysis to include only patients with type 2 diabetes.
Metformin activates endothelial nitric oxide synthase to increase nitric oxide production and counter VEGF inhibitor toxicity.
No randomized trials have tested metformin for cardioprotection in cardio-oncology.
He led the retrospective analysis presented at the American Heart Association Scientific Sessions that linked metformin use to lower all-cause mortality and reduced new-onset metastatic cancer in patients receiving these inhibitors. His work also examines the drug’s activation of AMPK and endothelial nitric oxide synthase as potential countermeasures to treatment-related cardiotoxicity.
It is still unclear whether these mechanisms extend to broader cardiovascular protection.
Keep reading